Completed PHASE3 INTERVENTIONAL 1-arm
NCT07344376
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) in Patients With Hunter Syndrome
Sponsor: GC Biopharma Corp
Conditions
GC1111 Hunter Syndrome Hunter Syndrome (MPS II) Hunterase MPS II
Interventions
Hunterase
Updated 1 time since 2026 Last updated: Jan 7, 2026 Started: May 23, 2018 Primary completion: Dec 30, 2022 Completion: Dec 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on GC1111 and Hunter Syndrome, this trial is completed. The trial is conducted by GC Biopharma Corp and has accumulated 1 data snapshot since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Completed — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- GC Biopharma Corp
- Samsung Medical Center, Sungkyunkwan University School of Medicine
Data source: GC Biopharma Corp
For direct contact, visit the study record on ClinicalTrials.gov .